Successful Treatment of Progressive Symmetric Erythrokeratoderma With Secukinumab (ESDR 2026) - Oct 5, 2026 - Abstract #442; "She had used acitretin 60 mg/day with initial improvement, but relapsed after dose reduction due to reproductive planning. Cyclosporine 200 mg/day was then introduced, with marked worsening of scaling and pruritus...Barrier dysfunction may promote interleukin-17 activation, contributing to persistent erythema and scaling. This case suggests that interleukin-17A blockade may be a promising off-label option for refractory progressive symmetric erythrokeratoderma, particularly when systemic retinoids are contraindicated or undesirable."
Pruritus
|
|
Thaís Barros Felippe Jabour; Kaique Arriel; Flavia Naranjo Ravelli; Artur Antonio Duarte
|